MCB has replaced the Dear Colleague Letter (DCL), Sentinel Cells for the Surveillance and Response to Emergent Infectious Diseases (NSF 20-105) with a new DCL:
Sentinel Systems that Detect, Recognize, Actuate, and Mitigate Emergent Biological Threats (DREAM Sentinels).
In this new Sentinels DCL, MCB again partners with the Directorate for Engineering’s Division of Chemical, Bioengineering, Environmental and Transport Systems to call for proposals to be submitted to core programs that address novel synthetic biology approaches to quickly sense and respond to the next emergent biological threat prior to its evolution in its host or transmission to human populations.
All proposals submitted in response to this DCL should include biosensing and bioactuation elements that address a biological threat. The biosensing element should leverage the power of modern biotechnology and deliver robust and specific recognition of the biological threat. The results of bioactuation should alert the user, destroy the threat, protect the host, or initiate an immune response or other strategies that would mitigate the threat. Other possible areas of interest are included in the DCL.
Proposals submitted in response to this DCL should have a title prefaced with “DREAM Sentinels:”. Proposals should be submitted to the Systems and Synthetic Biology cluster where proposals are accepted without deadline and are reviewed as they are received.
Investigators interested in submitting a proposal are strongly encouraged to contact Anthony Garza, email@example.com. More information on the DCL can be found here.
It is anticipated that up to $3,000,000 will be allocated annually for DREAM Sentinels awards, subject to the availability of funds.